Tier 4 — mechanistic

Apigenin’s Modulation of Doxorubicin Efficacy in Breast Cancer

Aleksandra Golonko, Adam Jan Olichwier, Agata Szklaruk, Adam Paszko, Renata Świsłocka, Łukasz Szczerbiński, Włodzimierz Lewandowski
Molecules 2024 29(11):2603

Bibliography

PubMed
PMID 38893482
PubMed Central
PMC11174085
DOI
10.3390/molecules29112603

Study snapshot

DesignIn vitro cancer-cell study plus chemoinformatics
ModelMCF-7 and MDA-MB-231 breast cancer cells
Sample
InterventionApigenin alone and with doxorubicin
Duration
EndpointsCell viability; Migration; Lipid droplets; ABC transporter interaction hypotheses; AKT and MYC pathways

What the study showed, in plain terms

This study investigated how apigenin affects breast cancer cells and how it may interact with doxorubicin.

Key findings

Apigenin produced dose-dependent cytotoxic and anti-migratory effects. Modeling suggested possible interactions with ABC transporters and indirect involvement of AKT and MYC pathways.

What this study can and cannot tell us

In vitro interaction findings do not establish that patients should combine apigenin with doxorubicin. Supplement-drug interactions during chemotherapy require clinical caution.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology